Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butedronic Acid SCHEMBL8712640 | 0.98 | TDP1 (0.56) | TDP1FOLH1CA2CA4MEN1 | |
| Butedronic Acid SCHEMBL11226134 | 0.98 | TDP1 (0.56) | TDP1FOLH1CA2CA4MEN1 | |
| Butedronic Acid SCHEMBL5857758 | 0.87 | TDP1 (0.45) | TDP1FOLH1CA2CA4MEN1 | |
| Butedronic Acid SCHEMBL5857756 | 0.84 | TDP1 (0.42) | TDP1FOLH1CA2CA4LMNA | |
| Phosphoric Acid SCHEMBL9456210 | 0.80 | TDP1 (0.74) | TDP1FOLH1CA2CA4MEN1 | |
| SCHEMBL23009 | 0.79 | TDP1 (0.56) | TDP1FOLH1CA2CA4MEN1 | |
| SCHEMBL15264638 | 0.79 | TDP1 (0.56) | TDP1FOLH1CA2CA4MEN1 | |
| SCHEMBL490757 | 0.79 | TDP1 (0.64) | TDP1FOLH1CA2CA4MEN1 | |
| SCHEMBL2764210 | 0.79 | TDP1 (0.56) | TDP1FOLH1CA2CA4MEN1 | |
| SCHEMBL9296105 | 0.77 | TDP1 (0.54) | TDP1FOLH1CA2CA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11259767-B2 | Systems and methods for enhanced diagnosis of transthyretin cardiac amyloidosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-01 | — | — | US | claimed |
| US-20200046860-A1 | Systems and Methods for the Detection of Hydroxychloroquine-Mediated Cardiotoxicity | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2020-02-13 | — | — | US | claimed |
| US-20190290232-A1 | SYSTEMS AND METHODS FOR ENHANCED DIAGNOSIS OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2019-09-26 | — | — | US | claimed |
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2009-12-10 | — | — | US | claimed |
| EP-2041108-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | Antibe Therapeutics Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2008009118-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | claimed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | claimed |
| EP-1378239-A1 | Contrast agents for imaging | Eucro European Contract Research GmbH & Co. KG (DE) | 2004-01-07 | — | — | EP | claimed |
| US-20030229280-A1 | Contrast Medium for Use in Imaging Methods | EUCRO EUROPEAN CONTRACT RESEARCH GMBH AND CO. KG (DE) | 2003-12-11 | — | — | US | claimed |
| WO-2003097074-A1 | CONTRAST MEDIUM FOR USING IN IMAGE-PRODUCING METHODS | EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KG (DE) | 2003-11-27 | — | — | WO | claimed |
| EP-0078642-B1 | RADIOPHARMACEUTICAL COMPOSITION BASED ON TECHNETIUM-99M AND REAGENT FOR MAKING IT | AMERSHAM INTERNATIONAL plc (GB) | 1986-12-10 | — | — | EP | claimed |
| US-4451451-A | Radiopharmaceutical composition based on technetium-99m and reagent for making it | AMERSHAM INTERNATIONAL PLC (GB) | 1984-05-29 | — | — | US | claimed |
| EP-0078642-A2 | Radiopharmaceutical composition based on technetium-99m and reagent for making it | AMERSHAM INTERNATIONAL plc (GB) | 1983-05-11 | — | — | EP | claimed |
| EP-0002485-B1 | PROCESS FOR THE PREPARATION OF MARKING COMPOSITIONS CONTAINING TIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-04-28 | — | — | EP | claimed |
| US-RE30064-E | USE OF COLOR DEVELOPER CONTAINING P-PHENYLENEDIAMINE DEVELOPER AND ORGANIC COMPOUND CONTAINING PHOSPHONO AND CARBOXY GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 1979-08-07 | — | — | US | claimed |
| US-4162161-A | SILVER HALIDE, STANNOUS SALT, PHOSPHONOCARBOXYLIC ACID | FUJI PHOTO FILM CO., LTD. (JP) | 1979-07-24 | — | — | US | claimed |
| EP-0002485-A1 | Process for the preparation of marking compositions containing tin | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-27 | — | — | EP | claimed |
| US-4125608-A | Appetite curbing preparation containing an alginate and a diphosphonic acid | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1978-11-14 | — | — | US | claimed |
| US-4118476-A | CATIONIC BISGUANIDINO AND QUATERNARY AMMONIUM ANTIPLAQUE AGENTS, PHOSPHONOCARBOXYLATES | COLGATE-PALMOLIVE COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-4083723-A | P-PHENYLENEDIAMINE AND DERIVATIVES AND A COMPOUND WITH A CARBOXY AND A PHOSPHONO GROUP AS A COLOR DEVELOPER | FUJI PHOTO FILM CO., LTD. (JA) | 1978-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | HRH4, HRH2, HNMT | TDP1 2411/4885FOLH1 1575/4885CA2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.